ONTARIO, Canada, June 20, 2011 /PRNewswire/ — Panacea Global
Inc., (“the Company”) (OTCQB: PANG), a biopharmaceutical company
specializing in blood (protein), serum and tissue tests to diagnose
and monitor cancer, today announced the change of the Company’s
official trading symbol from MLXG to PANG.
On June 15, 2011, the trading symbol for the Company’s common
stock, which is quoted on the OTC Bulletin Board, was changed from
MLXG to PANG. This change was made in conjunction with the
Company’s filing of a Certificate of Amendment to its Articles of
Incorporation, on June 2, 2011, changing the Company’s name to
Panacea Global, Inc.
Panacea Global, Inc. is a biopharmaceutical company providing
blood (protein), serum and tissue tests to diagnose and monitor
cancer through a licensing agreement with Panacea Pharmaceuticals,
Inc. The Company’s mission is to discover, develop and
commercialize innovative diagnostic products. Panacea’s current
product development focus is on novel proteins and biochemical
pathways related to cellular regulation and cell cycle
abnormalities in oncology diseases including, Lung Cancer, Breast
Cancer, Prostate Cancer, Colorectal Cancer.
This press release may contain certain forward-looking
statements (as defined under Federal securities laws) regarding
Panacea’s performance, including future product development.
Forward-looking statements may be identified by the use of words
such as “plan”, “intend” or words of similar meaning in conjunction
with statements of future performance. All such statements are
based upon current expectations of Panacea and involve a number of
business risks and uncertainties. Actual results could vary
materially from anticipated results described, implied or projected
in any forward-looking statement. With respect to forward-looking
statements contained herein, a number of factors could cause actual